Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Cigna to buy Express Scripts

U.S. health insurer Cigna Corp. will buy pharmacy benefits manager Express Scripts Holding Co., a tie-up that reflects pressure on healthcare companies to grow bigger to cut costs.

Read More »

Kite, Sangamo team up in cancer therapeutics deal potentially worth $3+ billion

Kite Pharma, a Gilead company, inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.

Read More »

Enumeral Filed for Bankruptcy, Sells Assets

Enumeral Biomedical filed for bankruptcy protection and is selling its assets to Xoma Corporation for $1.6 million.

Read More »

AstraZeneca links with Alibaba and Tencent in China

AstraZeneca clinched two new deals with Chinese tech giants Alibaba and Tencent as the British drugmaker steps up the company’s drive to expand business in China.

Read More »

Homology Inks Deal for New Massachusetts HQ

Backed by financing from a collaboration with Novartis and an $83 million financing round, Homology Medicines is moving to a new facility with more than triple the space of its headquarters.

Read More »

U.S. pharma executives expect deals to pick up

The Trump administration’s tax overhaul should accelerate major acquisitions by drugmakers in 2018, say senior execs from some of the largest manufacturers.

Read More »

Ablynx Turns Down Novo Nordisk’s Sweetened $3.1 Billion Bid

Novo Nordisk A/S has twice made a bid to acquire Ablynx NV, and twice been rejected.

Read More »

Roche to buy U.S. cancer drugmaker Ignyta

Roche will buy U.S. cancer drugmaker Ignyta Inc. for $1.7 billion to broaden the Swiss drugmaker’s oncology portfolio globally.

Read More »

Boehringer Inks Deal With GlaxoSmithKline Spinout

Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.

Read More »

reMYND Forges 350M+ Euros Tie-Up With Novo Nordisk

Belgium-based reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom